Company
Mission
Scipher Medicine is a precision immunology company on a mission to match each patient with their most effective therapy and bring forward the day when every autoimmune disease patient reaches remission, and no one suffers in silence.
Our Story
Over the past two decades, research into the human genome and the rise of artificial intelligence have opened the door to transform the diagnosis and treatment of autoimmune disease.
Our founders, Drs. Joseph Loscalzo and Laszlo Barabasi set on a path of mapping human disease biology.
The map grows to cover 89% of all proteins in human cells, revealing the underlying causes of some of the most difficult diseases.
Scipher Medicine is founded.
Scipher closes Series A funding | Completed observational study for anti-TNF response test in rheumatoid arthritis
Scipher closes Series B funding | United Health Group invests in Scipher
PrismRA launches commercially | Scipher and Galapagos sign collaboration in inflammatory bowel disease
Scipher closes Series C financing | PrismRA launches among the TNF-exposed population
Scipher closes Series D funding | Scipher publishes 3 new studies on the clinical utility of PrismRA | Galapagos in-licenses novel drug targets
PrismRA receives Medicare coverage | Scipher signs multi-target partnership with Ionis
PrismRA test available in Quest labs across the U.S.
Our founders, Drs. Joseph Loscalzo and Laszlo Barabasi set on a path of mapping human disease biology.
The map grows to cover 89% of all proteins in human cells, revealing the underlying causes of some of the most difficult diseases.
Scipher Medicine is founded.
Scipher closes Series A funding | Completed observational study for anti-TNF response test in rheumatoid arthritis
Scipher closes Series B funding | United Health Group invests in Scipher
PrismRA launches commercially | Scipher and Galapagos sign collaboration in inflammatory bowel disease
Scipher closes Series C financing | PrismRA launches among the TNF-exposed population
Scipher closes Series D funding | Scipher publishes 3 new studies on the clinical utility of PrismRA | Galapagos in-licenses novel drug targets
PrismRA receives Medicare coverage | Scipher signs multi-target partnership with Ionis
PrismRA test available in Quest labs across the U.S.
Scipher Team
Filter by
-
CLICK FOR BIOJoseph Loscalzo, PhD, MDFounder | Physician-in-Chief, Brigham and Women’s Hospital
-
CLICK FOR BIOAlbert-László Barabási, PhDFounder | Professor, Harvard and Northeastern University
-
CLICK FOR BIOMichael Rubin, PhD, MD, CFAFounder and CEO, Northpond Ventures
-
CLICK FOR BIOSamir KaulFounding Partner and Managing Director, Khosla Ventures
-
CLICK FOR BIOTimothy AndersonManaging Director, Blue Owl
-
CLICK FOR BIOKyla Pavlina, JDChief People Officer (Interim)
-
CLICK FOR BIOAdam SeltserChief Financial Officer (Interim)
-
CLICK FOR BIOTodd Sone, MBAGeneral Partner, aMoon
-
CLICK FOR BIOMiklos KoborFounder and CEO, Central European Private Equity Investments
-
CLICK FOR BIOCourtney MorrisSenior Director, Value & Data Analytics
-
CLICK FOR BIOKristin PowersNational Sales Director
-
CLICK FOR BIOEmily KerwinController
-
CLICK FOR BIODerek J CrowtherRegional Sales Director
-
CLICK FOR BIOGlenn P Muir, MBA, MScChair of Audit Committee
-
CLICK FOR BIOStacey KaufmanSr. Director, Quality
Join Us. Make an Impact.
Learn more about the values that we live each day to drive our mission forward and how you can make an impact by working at Scipher.